Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02770716 · ClinicalTrials.gov registry record · Phase 3
Study To Confirm Efficacy and Safety of Terlipressin in Hepatorenal Syndrome (HRS) Type 1
A Phase 3 study, sponsored by Mallinckrodt.
- Completed
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
NCT02770716 is a Phase 3 study that has completed, run by Mallinckrodt. The registered enrollment target is 300 participants.
The verdict
NCT02770716, a Phase 3 study, has completed, sponsored by Mallinckrodt.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
Study Summary
This study is to treat adult patients with hepatorenal syndrome (HRS) Type 1. Out of every three participants, two will receive terlipressin and one will receive placebo. Assignments will be made randomly.
Interventions
- OTHER Placebo
- DRUG Terlipressin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2016-07-13 |
| Est. Completion | 2019-07-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02770716
The ClinicalTrials.gov registry entry for NCT02770716 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mallinckrodt, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02770716 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02770716 about?
NCT02770716 is a clinical study titled "Study To Confirm Efficacy and Safety of Terlipressin in Hepatorenal Syndrome (HRS) Type 1". This study is to treat adult patients with hepatorenal syndrome (HRS) Type 1. Out of every three participants, two will receive terlipressin and one will receive placebo. Assignments will be made randomly.
What is the current status of trial NCT02770716?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2016-07-13. Estimated completion is 2019-07-24.
What interventions are being tested in trial NCT02770716?
The interventions under investigation include: Placebo (OTHER), Terlipressin (DRUG).
Who is sponsoring clinical trial NCT02770716?
This trial is sponsored by Mallinckrodt, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.